131 related articles for article (PubMed ID: 12400781)
21. Successful therapy with rituximab of refractory acute humoral renal transplant rejection: a case report.
Celik A; Saglam F; Cavdar C; Sifil A; Atila K; Sarioglu S; Bora S; Gulay H; Camsari T
Transplant Proc; 2008; 40(1):302-4. PubMed ID: 18261611
[TBL] [Abstract][Full Text] [Related]
22. Profound hyperacute cardiac allograft rejection rescue with biventricular mechanical circulatory support and plasmapheresis, intravenous immunoglobulin, and rituximab therapy.
Kaczorowski DJ; Datta J; Kamoun M; Dries DL; Woo YJ
J Cardiothorac Surg; 2013 Mar; 8():48. PubMed ID: 23497431
[TBL] [Abstract][Full Text] [Related]
23. Successful treatment of hemodynamic compromise caused by antibody-mediated and cellular rejection in a recipient 12 years after heart transplantation.
Imamura T; Kinugawa K; Kato N; Kagami Y; Endo M; Kaneko N; Minatsuki S; Muraoka H; Inaba T; Maki H; Hatano M; Doi K; Yao A; Takazawa Y; Ono M; Kyo S; Komuro I
Int Heart J; 2013; 54(5):328-31. PubMed ID: 24097224
[TBL] [Abstract][Full Text] [Related]
24. Rituximab therapy for acute humoral rejection after kidney transplantation.
Faguer S; Kamar N; Guilbeaud-Frugier C; Fort M; Modesto A; Mari A; Ribes D; Cointault O; Lavayssière L; Guitard J; Durand D; Rostaing L
Transplantation; 2007 May; 83(9):1277-80. PubMed ID: 17496547
[TBL] [Abstract][Full Text] [Related]
25. Effect of plasmapheresis for acute humoral rejection after heart transplantation.
Wang SS; Chou NK; Ko WJ; Chi NH; Hung SC; Hsu RB; Yu HY; Chen YS; Chu SH; Tsao CI; Shun CT
Transplant Proc; 2006 Dec; 38(10):3692-4. PubMed ID: 17175369
[TBL] [Abstract][Full Text] [Related]
26. Antibody-mediated rejection in heart transplant recipients: potential efficacy of B-cell depletion and antibody removal.
Bierl C; Miller B; Prak EL; Gasiewski A; Kearns J; Tsai D; Jessup M; Kamoun M
Clin Transpl; 2006; ():489-96. PubMed ID: 18365409
[TBL] [Abstract][Full Text] [Related]
27. Rituximab in highly sensitized kidney transplant recipients.
Munoz AS; Rioveros AA; Cabanayan-Casasola CB; Danguilan RA; Ona ET
Transplant Proc; 2008 Sep; 40(7):2218-21. PubMed ID: 18790197
[TBL] [Abstract][Full Text] [Related]
28. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation.
Vo AA; Peng A; Toyoda M; Kahwaji J; Cao K; Lai CH; Reinsmoen NL; Villicana R; Jordan SC
Transplantation; 2010 May; 89(9):1095-102. PubMed ID: 20110854
[TBL] [Abstract][Full Text] [Related]
29. Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection.
Fehr T; Rüsi B; Fischer A; Hopfer H; Wüthrich RP; Gaspert A
Transplantation; 2009 Jun; 87(12):1837-41. PubMed ID: 19543061
[TBL] [Abstract][Full Text] [Related]
30. Early and late humoral rejection: a clinicopathologic entity in two times.
Péfaur J; Díaz P; Panace R; Salinas P; Fiabane A; Quinteros N; Chea R; Naranjo E; Wurgaft A; Beltran E; Elgueta S; Wegmann ME; Gajardo JG; Contreras L
Transplant Proc; 2008 Nov; 40(9):3229-36. PubMed ID: 19010241
[TBL] [Abstract][Full Text] [Related]
31. Treatment of simultaneous acute antibody-mediated rejection and acute cellular rejection with alemtuzumab in kidney transplantation: a case report.
Jirasiritham S; Khunprakant R; Techawathanawanna N; Jirasiritham S; Mavichak V
Transplant Proc; 2010 Apr; 42(3):987-9. PubMed ID: 20430222
[TBL] [Abstract][Full Text] [Related]
32. Changes in anti-HLA antibody titers more than 1 year after desensitization therapy with rituximab in living-donor kidney transplantation.
Takagi T; Ishida H; Shirakawa H; Shimizu T; Tanabe K
Transpl Immunol; 2010 Aug; 23(4):220-3. PubMed ID: 20598888
[TBL] [Abstract][Full Text] [Related]
33. The Effect of Bortezomib on Antibody-Mediated Rejection after Kidney Transplantation.
Lee J; Kim BS; Park Y; Lee JG; Lim BJ; Jeong HJ; Kim YS; Huh KH
Yonsei Med J; 2015 Nov; 56(6):1638-42. PubMed ID: 26446648
[TBL] [Abstract][Full Text] [Related]
34. Antibody-mediated rejection: treatment alternatives and outcomes.
Singh N; Pirsch J; Samaniego M
Transplant Rev (Orlando); 2009 Jan; 23(1):34-46. PubMed ID: 19027615
[TBL] [Abstract][Full Text] [Related]
35. B cell monitoring of transplant patients treated with anti-CD20.
Abdallah KO; Prak ET
Clin Transpl; 2006; ():427-37. PubMed ID: 18365400
[TBL] [Abstract][Full Text] [Related]
36. Cardiac antibody-mediated rejection.
Chin C
Pediatr Transplant; 2012 Aug; 16(5):404-12. PubMed ID: 22500558
[TBL] [Abstract][Full Text] [Related]
37. Immunoglobulin M-to-immunoglobulin G anti-human leukocyte antigen class II antibody switching in cardiac transplant recipients is associated with an increased risk of cellular rejection and coronary artery disease.
Lietz K; John R; Burke E; Schuster M; Rogers TB; Suciu-Foca N; Mancini D; Itescu S
Circulation; 2005 Oct; 112(16):2468-76. PubMed ID: 16230499
[TBL] [Abstract][Full Text] [Related]
38. Therapy with plasmapheresis and intravenous immunoglobulin for acute humoral rejection in kidney transplantation.
Ibernón M; Gil-Vernet S; Carrera M; Serón D; Moreso F; Bestard O; Cruzado JM; Grinyó JM
Transplant Proc; 2005 Nov; 37(9):3743-5. PubMed ID: 16386524
[TBL] [Abstract][Full Text] [Related]
39. Modulation of acute and hyperacute rejection of xenografts in concordant hamster-to-rat combination.
Sablinski T; Hancock WW; Wasowska BA; Schmidbauer G; Baldwin WM; Kut JP; Milford EL; Kupiec-Weglinski JW
Transplant Proc; 1993 Feb; 25(1 Pt 1):432-4. PubMed ID: 8438366
[No Abstract] [Full Text] [Related]
40. [Corticoid-resistant rejection and humoral rejection. The diagnostic criteria and therapeutic management].
Crespo Leiro MG; Portela Torrón F; Vázquez González N; Vázquez Rodríguez JM; Yebra Pimentel MT; González Cuesta M
Rev Esp Cardiol; 1995; 48 Suppl 7():77-85. PubMed ID: 8775821
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
